India, May 6 -- Shares of Pasithea Therapeutics Corp. (KTTA) surged over 125% on Tuesday morning after the company announced positive pharmacodynamic results demonstrating robust target engagement from its ongoing phase 1 clinical trial of PAS-004.
KTTA is currently trading at $3.2099, up $1.7899 or 126.0493%, on the Nasdaq. The stock opened its trading at $2.2200 after closing Monday at $1.4200. The stock has traded between $0.9230 and $7.6900 in the past 52-week period.
Pasithea Therapeutics announced positive interim pharmacodynamic (PD) data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients. The data includes results from cohorts 3 and 4A, evaluating 8mg and 15mg capsules, as well as cohort 4B evaluating 4mg tablet...